Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/158951| Title: | The Pharmaceutical Industry in 2017. An Analysis of FDA Drug Approvals from the Perspective of Molecules |
| Author: | de la Torre, Beatriz G. Albericio Palomera, Fernando |
| Keywords: | Disseny de medicaments Pèptids Farmacologia Drug design Peptides Pharmacology |
| Issue Date: | 27-Feb-2018 |
| Publisher: | MDPI |
| Abstract: | This is an analysis from a chemical point of view of the 46 drugs (34 New Chemical Entities and 12 Biologics) approved by the FDA during 2017. The drugs included in the 2017 "harvest" have been classified on the basis of their chemical structure: biologics (antibodies and proteins); peptides; amino acids and natural products; drug combinations; and small molecules. |
| Note: | Reproducció del document publicat a: https://doi.org/10.3390/molecules23030533 |
| It is part of: | Molecules, 2018, vol. 23, num. 3, p. 533 |
| URI: | http://hdl.handle.net/2445/158951 |
| Related resource: | https://doi.org/10.3390/molecules23030533 |
| ISSN: | 1420-3049 |
| Appears in Collections: | Articles publicats en revistes (Química Inorgànica i Orgànica) |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| 680996.pdf | 3.57 MB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License
